US FDA calls panel meeting for Theratechnologies' HIV lipodystrophy drug
This article was originally published in Scrip
Executive Summary
The US FDA has scheduled an endocrinologic and metabolic drugs advisory committee meeting for February 24th to discuss Theratechnologies' Egrifta (tesamorelin acetate), a proposed HIV lipodystrophy drug.